DONGGUAN LIZENG TECHNOLOGY CO., LTD – Trademark Portfolio

Entity Type: 99

DONGGUAN LIZENG TECHNOLOGY CO., LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include ACLINKI. The owner is based in DONGGUAN CITY, GUANGDONG PROVINCE.

ROOM 101, NO. 190

NANCHENG SECTION, SHUILIAN LANDSCAPE ROAD, NANCHENG STREET

DONGGUAN CITY, GUANGDONG PROVINCE 523000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ACLINKI
ACLINKI
Registered 2024

Trademark Classifications

DONGGUAN LIZENG TECHNOLOGY CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does DONGGUAN LIZENG TECHNOLOGY CO., LTD have?

DONGGUAN LIZENG TECHNOLOGY CO., LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does DONGGUAN LIZENG TECHNOLOGY CO., LTD file in?

DONGGUAN LIZENG TECHNOLOGY CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are DONGGUAN LIZENG TECHNOLOGY CO., LTD's most well-known trademarks?

DONGGUAN LIZENG TECHNOLOGY CO., LTD's registered trademark portfolio includes well-known marks such as ACLINKI. These are among 1 currently registered trademark in the portfolio.

What is DONGGUAN LIZENG TECHNOLOGY CO., LTD's trademark registration success rate?

DONGGUAN LIZENG TECHNOLOGY CO., LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.